To analyse the morpho-functional outcomes of dexamethasone intravitreal implant (Ozurdex) injected after lens surgery in diabetic patients with coexisting cataract and macular oedema.
Methods:
This is a non-randomized, perspective, single-group study on 17 eyes with a diagnosis of cataract and early and advanced diabetic macular oedema. All eyes underwent combined phacoemulsification and Ozurdex injection at the end of surgery and morpho-functional outcomes were analysed in 3 months follow-up.
Results:
Foveal thickness decreased significantly from 349.6 ± 19.8 (95% CI) at baseline to 310.7 ± 17.5 (95% CI) 90 days after surgery (p < 0.01).
Mean BCVA (LogMAR) improved significantly from 0.38 ± 0.08 (95% CI) at baseline to 0.15 ± 0.06 (95% CI) after 90 days (p < 0.01). Any ocular or systemic complications were observed during follow-up.
Conclusions:
Dexamethasone intravitreal implant combined with phacoemulsification may be safe and effective to improve morpho-functional outcomes in diabetic patients with coexisting cataract and macular oedema.
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet2016; 387: 1513–1530.
2.
YauJWRogersSLKawasakiR, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care2012; 35(3): 556–564.
3.
ObrosovaIGChungSSKadorPF.Diabetic cataracts: mechanisms and management. Diabetes Metab Res Rev2010; 26: 172–180.
4.
HaddadNMNSunJKAbujaberS, et al. Cataract surgery and its complications in diabetic patients. Semin Ophthalmol2014; 29(5–6): 329–337.
5.
KimSJEquiRBresslerNM.Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography. Ophthalmology2007; 114(5): 881–889.
6.
ErikssonUAlmABjärnhallG, et al. Macular edema and visual outcome following cataract surgery in patients with diabetic retinopathy and controls. Graefes Arch Clin Exp Ophthalmol2011; 249: 349–359.
7.
HabibMSCannonPSSteelDH.The combination of intravitreal triamcinolone and phacoemulsification surgery in patients with diabeticfoveal oedema and cataract. BMC Ophthalmol2005; 5: 15.
8.
AhmadabadiHFMohammadiMBeheshtnejadH, et al. Effect of intravitreal triamcinolone acetonide injection on central macular thickness in diabetic patients having phacoemulsification. J Cataract Refract Surg2010; 36: 917–922.
9.
AkinciAMuftuogluOAlti̇nsoyA, et al. Phacoemulsification with intravitreal bevacizumab and triamcinolone acetonide injection in diabetic patients with clinically significant macular edema and cataract. Retina2011; 31(4): 755–758.
10.
RauenPIRibeiroJAAlmeidaFP, et al. Intravitreal injection of ranibizumab during cataract surgery in patients with diabetic macular edema. Retina2012; 32(9): 1799–1803.
11.
Lanzagorta-ArestiAPalacios-PozoERozalenJLM, et al. Prevention of vision loss after cataract surgery in diabetic macular edema with intravitreal bevacizumab: a pilot study. Retina2009; 29(4): 530–535.
12.
TakamuraYKuboEAkagiY.Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery. Ophthalmology2009; 116(6): 1151–1157.
13.
AkinciABatmanCOzkilicE, et al. Phacoemulsification with intravitreal bevacizumab injection in diabetic patients with macular edema and cataract. Retina2009; 29(10): 1432–1435.
14.
ChenCHLiuYCWuPC.The combination of intravitreal bevacizumab and phacoemulsification surgery in patients with cataract and coexisting diabetic macular edema. J Ocul Pharmacol Ther2009; 25(1): 83–90.
15.
ChaeJBJoeSGYangSJ, et al. Effect of combined cataract surgery and ranibizumab injection in post-operative macular edema in non-proliferative diabetic retinopathy. Retina2014; 34: 149–156.
16.
BoyerDSYoonYHBelfortRJr, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology2014; 121: 1904–1914.
17.
MalclèsADotCVoirinN, et al. Real-life study in diabetic macular edema treated with dexamethasone implant. Retina2017; 37: 753–760.
18.
IglickiMBuschCZurD, et al. dexamethasone implant for diabetic macular edema in naïve compared with refractory eyes: the International Retina group real-life 24-month multicenter study. The IRGREL-DEX study. Retina2018; 39(1): 44–51.
19.
AgarwalAGuptaVRamJ, et al. Dexamethasone intravitreal implant during phacoemulsification. Ophthalmology2013; 120(1): 211, 211.e1–e5.
20.
PanozzoGAGussonEPanozzoG, et al. Dexamethasone intravitreal implant at the time of cataract surgery in eyes with diabetic macular edema. Eur J Ophthalmol2017; 27(4): 433–437.
21.
FurinoCBosciaFNiroA, et al. Combined phacoemulsification and intravitreal dexamethasone implant (ozurdex®) in diabetic patients with coexisting cataract and diabetic macular edema. JOJ Ophthalmol2017; 2017: 1–7.
22.
PanozzoGCicinelliMVAugustinAJ, et al. An optical coherence tomography-based grading of diabetic maculopathy proposed by an international expert panel: the European School for Advanced Studies in ophthalmology classification. Eur J Ophthalmol2020; 30: 8–18.
23.
Bollettino Ufficiale della Regione Puglia - n. 88, 3-7-2018. Delibera Regione Puglia n. 984, 2018, 9–10.
